⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 2, 2024Open Access

Figure S7 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates

Joshua D. Thomas Aleksandr V. Yurkovetskiy Mao Yin Natalya D. Bodyak Shuyi Tang Marina Protopopova Eugene Kelleher Brian Jones Liping Yang Daniel Custar Kalli C. Catcott Damon R. Demady Scott D. Collins Ling Xu Charlie Bu LiuLiang Qin Elena Ter‐Ovanesyan Marc Damelin Dorin Toader Timothy B. Lowinger

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure shows Efficacy in OVCAR-3 xenograft for A) targeted ADCs X-17 and X-19 and B) their corresponding non-binding control ADCs NB-17 and NB-19

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thomas et al. (2024) studied this question.

synapsesocial.com/papers/68e70c5ab6db643587686038 https://doi.org/10.1158/1535-7163.25523496

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S4 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024
2Figure S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024
3Table S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024
4Table S8 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024
5Figure S3 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024

More related papers

Table S7 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024
Table S7 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024
Figure S6 from Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates2024